Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

3858 results

Sort By:

Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

Study ID: NCT07264075
Start Date: 2026-01
End Date: 2030-05
Study Type

Interventional

Study Phase

Phase3

No. of Participants

780

Intervention / Treatment

Ivonescimab 10 mg/kg

Ligufalimab

Pembrolizumab (KEYTRUDA ®)

Sponsor

Head and Neck Oncology Radiotherapy Group

Source: clinicaltrials.gov

Share:
Add to list

A Study of PLB-002 in Advanced Solid Tumors

Study ID: NCT07304128
Start Date: 2026-01-12
End Date: 2027-12-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

100

Intervention / Treatment

PLB-002

Sponsor

Primelink BioTherapeitics(ShenZhen) Limited

Source: clinicaltrials.gov

Share:
Add to list

INcreasing the Uptake of DSMES Program and Addressing Social Needs in Low-Income VulneRablE Immigrants

Study ID: NCT07296211
Start Date: 2026-01
End Date: 2029-06
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

480

Intervention / Treatment

CHW-enabled CCL

Mobile health (mHealth) diabetes self-management education and support (DSMES) videos

Sponsor

NYU Langone Health

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Study ID: NCT07227311
Start Date: 2026-01-14
End Date: 2030-07-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

200

Intervention / Treatment

Belantamab mafodotin

Dexamethasone

Pomalidomide

Bortezomib

Carfilzomib

Sponsor

GlaxoSmithKline

Source: clinicaltrials.gov

Share:
Add to list

A Health System/Community Partnership for Enhanced Outreach to Prevent Suicide Attempts

Study ID: NCT05837026
Start Date: 2026-06
End Date: 2027-11
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

300

Intervention / Treatment

Enhanced Outreach Intervention (EOI) plus Care as Usual (CAU)

Care as Usual (CAU)

Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

OverStitch NXT Endoscopic Suture System

Study ID: NCT07276815
Start Date: 2026-07-31
End Date: 2029-10-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

136

Intervention / Treatment

OverStitch NXT Endoscopic Suture System

Sponsor

Boston Scientific Corporation

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Study ID: NCT07285148
Start Date: 2026-06
End Date: 2029-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

253

Intervention / Treatment

ANS014004 + PLB1004

ANS014004 + Osimertinib

Sponsor

Beijing Pearl Biotechnology Limited Liability Company

Source: clinicaltrials.gov

Share:
Add to list

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Study ID: NCT05951205
Start Date: 2027-07-31
End Date: 2033-12-31
Study Type

Interventional

Study Phase

Phase3

No. of Participants

12

Intervention / Treatment

Exa-the one

Sponsor

Vertex Pharmaceuticals Incorporated

Source: clinicaltrials.gov

Share:
Add to list

Vagal Stimulation Therapy and Preeclampsia

Study ID: NCT06953115
Start Date: 2026-02-01
End Date: 2027-05-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

210

Intervention / Treatment

Vagal stimulation physiotherapy with trigger point release

Positional Release Therapy

Sponsor

René Mey International Foundation

Source: clinicaltrials.gov

Share:
Add to list

Raman Spectroscopy-Based Non-Invasive Blood Glucose Detection

Study ID: NCT07311421
Start Date: 2026-01-01
End Date: 2026-10-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

49

Intervention / Treatment

Raman spectroscopy for blood glucose measurement

Sponsor

Beijing Shijitan Hospital, Capital Medical University

Source: clinicaltrials.gov

Share:
Add to list